AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30430372
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU caplets, administered weekly)
Trial: 30430372
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered weekly)
Trial: 26702120
Drug: NoEx (fructose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoEx (fructose treatment alone with no exercise condition)
Trial: 22574737
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate (80 mM) enema, twice daily for 3 days
Trial: 21117498
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride immediate-release tablet formulations
Trial: 21117498
Drug: Experimental conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental conditions for metformin hydrochloride release
Trial: 2454027
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg daily for two days, then 20 mg once daily
Trial: 2454027
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for two days, then 375 mg twice daily
Trial: 28697767
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Ezetimibe administered in the morning (8:00 am) for 6 weeks and then in the evening for the next 6 weeks
Trial: 28697767
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Ezetimibe administered in the evening (8:00 pm) for the first 6 weeks and then in the morning for the following 6 weeks
Trial: 28697767
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Ezetimibe (both administration times)
Trial: 19762739
Drug: Sevoflurane inhalation
RxNorm normalized name: Sevoflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation (<1 vol% end-tidal concentration)
Trial: 17595249
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg/d
Trial: 19394661
Drug: rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 8 mg/d
Trial: 15185314
Drug: PEG IFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG IFN‐alpha monotherapy (n = 20)
Trial: 15185314
Drug: Treated subjects
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated subjects (both PEG IFN‐alpha plus ribavirin and PEG IFN‐alpha monotherapy)
Trial: 9664985
Drug: UDCA 15
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 15 mg/kg per day
Trial: 2571501
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not on chronic nifedipine therapy)
Trial: 321103
Drug: buprenorphine hydrochloride
RxNorm normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine hydrochloride 0.2 mg
Trial: 321103
Drug: buprenorphine hydrochloride
RxNorm normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine hydrochloride 0.4 mg
Trial: 321103
Drug: morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulphate 5 mg
Trial: 10692620
Drug: morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulphate 10 mg
Trial: 22573933
Drug: Pasireotide 200-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 200-1200 μg
Trial: 22573933
Drug: Pasireotide 1-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 1-1200 μg
Trial: 19485982
Drug: Standard-dose peginterferon-alpha-2b
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose peginterferon-alpha-2b (1.5 microg/kg/week) plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A)
Trial: 19485982
Drug: Low-dose peginterferon-alpha-2b
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B)
Trial: 19485982
Drug: No extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No extended treatment (group C)
Trial: 11732026
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral antibiotics (penicillin VK, 500 mg every 6 hours for 5 days)
Trial: 11732026
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo, same schedule as group 1)
Trial: 9885688
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms sufentanil added to 7.5 mg bupivacaine
Trial: 9885688
Drug: 15 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 micrograms fentanyl added to 7.5 mg bupivacaine
Trial: 9885688
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg bupivacaine alone
Trial: 8004297
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 800 micrograms by Turbuhaler
Trial: 2129838
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg at night
Trial: 2129838
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg at night
Trial: 21654350
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily
Trial: 23731453
Drug: Topical sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sildenafil (10%) ointment
Trial: 23161898
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2 d1) and pemetrexed (500 mg/m2 d1) q3 weeks
Trial: 23161898
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2 d1 + 8) and vinorelbine (25 mg/m2 d1, 8, 15, 22) q4 weeks
Trial: 17409841
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 mg/m on days 1, 4, 8, and 11 plus docetaxel 75 mg/m on day 1, cycled every 21 days.
Trial: 8935812
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/day (Olz10.0)
Trial: 8935812
Drug: Olanzapine 1
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 1 mg/day (Olz1.0)
Trial: 1743840
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment with a newly designed brace
Trial: 7181299
Drug: Sulphate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphate (1 mg m‐3)
Trial: 7181299
Drug: Sulphate (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphate (0.1 mg m‐3)
Trial: 24843528
Drug: liraglutide 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 0.9 mg/day
Trial: 21037100
Drug: Vascular endothelial
RxNorm normalized name: Vascular endothelial growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular endothelial expression of mucosal addressin cell adhesion molecule-1
Trial: 18097503
Drug: G. lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. lucidum 6 mg
Trial: 18097503
Drug: G. lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. lucidum 0.6 mg
Trial: 18097503
Drug: G. lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. lucidum 60 mg
Trial: 8269452
Drug: Loratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (5 or 10 mg once daily for 14 days)
Trial: 8269452
Drug: Terfenadine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (15 mg twice daily for 14 days)
Trial: 8269452
Drug: Loratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (5 or 10 mg once daily)
Trial: 8269452
Drug: Terfenadine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (15 mg twice daily)
Trial: 4041344
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of nisoldipine
Trial: 4041344
Drug: Continued administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued administration of nisoldipine
Trial: 30509713
Drug: Saffron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron supplementation (100 mg/d for 8 weeks)
Trial: 10394177
Drug: Citalopram therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram therapy (40 mg i.v. bolus immediately after admission to the ICU)
Trial: 10394177
Drug: Citalopram therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram therapy (continuous infusion over 24 hours)
Trial: 10394177
Drug: Citalopram therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram therapy
Trial: 8907717
Drug: Diltiazem administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem administered at 08:00 (AM)
Trial: 8907717
Drug: Diltiazem administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem administered at 22:00 (HS)
Trial: 1794358
Drug: Purified pneumococcal
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified pneumococcal polysaccharide vaccines
Trial: 1794358
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of more highly immunogenic vaccines (linked polysaccharides to protein carriers)
Trial: 29128300
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (20-25 kcal/kg per day)
Trial: 25925751
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PHM and NMF (COMB)
Trial: 21369791
Drug: Alendronate (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5, 10, or 20 mg daily; 35 mg once-weekly; 35 mg twice-weekly; 70 mg once-weekly)
Trial: 20691641
Drug: Leuprorelin 11.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 11.25 mg subcutaneously every 12 weeks
Trial: 19419930
Drug: Multitargeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitargeted therapy
Trial: 19419930
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with traditional chemotherapy and radiation therapy
Trial: 19419930
Drug: Multitargeted inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitargeted inhibitors
Trial: 16491252
Drug: Happydent chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happydent chewing gum (3.38 mg of fluoride as monofluorophosphate)
Trial: 12568272
Drug: Auricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular therapy using magnetic pearls (Group C)
Trial: 12568272
Drug: Auricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular therapy using Junci Medulla (Group A)
Trial: 12568272
Drug: Auricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular therapy using Semen Vaccariae (Group B)
Trial: 10792330
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment with low dose ethinyl oestradiol (0.05 microgram/kg/day)
Trial: 10792330
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) injections of GH (6 IU/m2/day)
Trial: 10792330
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID) injections of GH (6 IU/m2/day)
Trial: 10792330
Drug: Post-GH treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-GH treatment with adult dosage of oestrogens
Trial: 8814838
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy with epirubicin (20 mg/40 mL saline)
Trial: 1495577
Drug: Antiepileptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic therapy using two standard anti-epileptic drugs
Trial: 6519902
Drug: Ciclazindol (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclazindol (three different doses)
Trial: 31268180
Drug: Epirubicin, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy with bevacizumab (B)
Trial: 31268180
Drug: Epirubicin, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy without bevacizumab (B)
Trial: 26728766
Drug: CHoBI7 intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHoBI7 intervention (handwashing with soap and water treatment for 7 days)
Trial: 23795621
Drug: MoodGYM (computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoodGYM (computerized cognitive behavioural therapy)
Trial: 22687889
Drug: Clarithromycin, amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, amoxicillin and omeprazole (CAO)
Trial: 22687889
Drug: Levofloxacin, amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, amoxicillin and omeprazole (LAO)
Trial: 20438568
Drug: Limited shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited shock wave therapy (SWT)
Trial: 17642523
Drug: DHA 900
RxNorm normalized name: DHA
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DHA 900 mg monotherapy for 5 days
Trial: 17642523
Drug: DHA 600
RxNorm normalized name: DHA
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DHA 600 mg + mefloquine [MQ] 750 mg combination regimen
Trial: 11942956
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for patients with inoperable primary tumors.
Trial: 29023915
Drug: OCA 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA 10 mg
Trial: 29023915
Drug: OCA 50
RxNorm normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: OCA 50 mg
Trial: 22578254
Drug: Psilocybin (215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (215 μg/kg) + Ketanserin (50 mg)
Trial: 16491671
Drug: Acetaminophen consumers
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen consumers
Trial: 9191511
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily beta‐blocker therapy (oral atenolol, 50 to 200 mg)
Trial: 9191511
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily calcium channel blocker therapy (oral diltiazem 120 to 360 mg)
Trial: 1888800
Drug: Benzodiazepine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine therapy
Trial: 17225720
Drug: Topical 0.03%
RxNorm normalized name: tacrolimus topical 0.03% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.03% tacrolimus
Trial: 24463121
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (with medications and exercise prescription)
Trial: 24463121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (with medications only)
Trial: 15608037
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (0.25 mg of cetrorelix daily starting on day 6 of stimulation)
Trial: 15608037
Drug: Long GnRH
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long GnRH agonist protocol (600 microg of buserelin acetate daily starting in the mid-luteal phase of the preceding cycle)
Trial: 12794818
Drug: leflunomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide (100 mg/day for 3 days, then 10 mg/day or 20 mg/day thereafter)
Trial: 1710395
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid infusion (BCAAs = 15.5%)
Trial: 7425963
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily Beclomethasone dipropionate (BDP) treatment
Trial: 7425963
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily Beclomethasone dipropionate (BDP) treatment
Trial: 23839319
Drug: 0.05 mcg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mcg/kg/min (GROUP A)
Trial: 23839319
Drug: 0.1 µg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 µg/kg/min (GROUP B)
Trial: 22828481
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=10)
Trial: 15830983
Drug: Epidural Injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Injection of Steroids
Trial: 10051289
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/d)
Trial: 7670117
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy based on polymerase chain reaction (PCR) technique
Trial: 1688039
Drug: Xamoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (200 mg bd orally for 1 month)
Trial: 7259982
Drug: Desoximetasone emollient
RxNorm normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone emollient cream 0.25% applied twice daily
Trial: 7259982
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate 0.1% cream applied twice daily
Trial: 7259982
Drug: Desoximetasone emollient
RxNorm normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone emollient cream
Trial: 23569140
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with pelvic floor exercises for 24 weeks
Trial: 23569140
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (ultrasonography, short wave diathermy and lumbar strengthening exercises) for 24 weeks
Trial: 15274384
Drug: Epoetin beta,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin beta, 30,000 IU per week in three divided doses, with iron supplementation when needed.
Trial: 8010420
Drug: Hyperbaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric lidocaine 5% solution in a single bolus of 75 mg
Trial: 8010420
Drug: Hyperbaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric lidocaine 2.5% solution in increments of 25 mg (maximum of three doses)
Trial: 8010420
Drug: Titrated doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated doses of 50 mg (n = 15)
Trial: 8010420
Drug: Titrated doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated doses of 75 mg (n = 15)
Trial: 8010420
Drug: Titrated doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated doses (overall)
Trial: 22151477
Drug: Vitamin/mineral supplement
RxNorm normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin/mineral supplement
Trial: 2909593
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (adequate diet)
Trial: 31296256
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of TGFβ blocking antibody fresolimumab (10 mg/kg)
Trial: 31296256
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of TGFβ blocking antibody fresolimumab (1 mg/kg)